Holen Sie sich die Stockscreener-App
26.10
0.81%
0.21
Vorhandelsmarkt:
25.71
-0.39
-1.49%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.89
Offen:
$25.9
24-Stunden-Volumen:
48.73M
Relative Volume:
0.78
Marktkapitalisierung:
$148.40B
Einnahmen:
$62.79B
Nettoeinkommen (Verlust:
$9.84B
KGV:
15.21
EPS:
1.7156
Netto-Cashflow:
$10.38B
1W Leistung:
+0.81%
1M Leistung:
+3.53%
6M Leistung:
+3.82%
1J Leistung:
+0.35%
1-Tages-Spanne:
$25.75
$26.31
1-Wochen-Bereich:
$25.09
$26.31
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.10 | 147.20B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,087.38 | 965.30B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.49 | 525.25B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
218.11 | 382.02B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
145.00 | 278.44B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.23 | 263.59B | 46.69B | 15.29B | 9.25B | 3.4329 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Pfizer Target of Unusually High Options Trading (NYSE:PFE) - MarketBeat
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress - TipRanks
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies - BioSpace
How Is The Market Feeling About Pfizer Inc? - Benzinga
Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap? - Nasdaq
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
Pfizer (NYSE:PFE) Shares Up 1.5%What's Next? - MarketBeat
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing DealLearn Why - simplywall.st
Pfizer (PFE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely - StocksToTrade
Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK - MedCity News
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Ex-Dividend Reminder: Albertsons Companies, Signet Jewelers and Pfizer - Nasdaq
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M (NASDAQ:NVAX) - Seeking Alpha
Pfizer CEO on His Relationship With RFK Jr. - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Declares $0.43 Quarterly Dividend - MarketBeat
Pfizer and Novavax ink $530m vaccine delivery licensing deal - Yahoo Finance
3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer - The Globe and Mail
Novavax inks license agreement with Pfizer - The Pharma Letter
Pfizer CEO Takes Aim at Kennedy Over Vaccines - The Wall Street Journal
Novavax signs licensing agreement with Pfizer for vaccine development - Reuters
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia
Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns - Yahoo Finance
Novavax Licenses Rights to Key Vaccine Component to Pfizer - The Wall Street Journal
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story - simplywall.st
Novavax’s Adjuvant Licensing Strategy Continues With Pfizer Pact - Citeline News & Insights
Lobbying Update: $1,720,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (PFE) Divests 11.7% Stake in ViiV Healthcare for $1.875B - Intellectia AI
Pfizer exits GSK majority-owned ViiV (PFE:NYSE) - Seeking Alpha
Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits - wtvbam.com
Novavax Pops on Pfizer Licensing Deal - Yahoo Finance
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Yahoo Finance
[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - European AIDS Treatment Group
Novavax Stock Pops After Pfizer Licensing Agreement - Schaeffer's Investment Research
Wealth Enhancement Advisory Services LLC Increases Position in Pfizer Inc. $PFE - MarketBeat
Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M - The Business Journals
Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company - Fierce Pharma
Pfizer sells ViiV stake to Shionogi - The Pharma Letter
Pfizer Executes Strategic Portfolio Shift with Major Divestment and Licensing Deal - AD HOC NEWS
Pfizer Cashes In ViiV Stake With Shionogi Sale For $1.88bn - Citeline News & Insights
GSK to retain majority stake in ViiV Healthcare as Pfizer exits and Shionogi increases share - Investing.com
Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant - marketscreener.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? - Yahoo Finance
Novavax, Inc. Enters into A License and Option Agreement with Pfizer Inc - marketscreener.com
Novavax (NVAX) Surges on Licensing Deal with Pfizer - GuruFocus
Novavax rises on licensing deal with Pfizer (NVAX:NASDAQ) - Seeking Alpha
GSK (NYSE: GSK) keeps ViiV control as Pfizer exits and Shionogi invests $2.125 bn - Stock Titan
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million - Investing.com
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.57%
1.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):